bluebird bio Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of bluebird bio Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023 inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 28, 2024.

If you purchased bluebird common stock and would like to join the action, please click “Join This Class Action.”

集体诉讼期:April 24, 2023 through December 8, 2023


33 Days
If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit, defendants made false and/or misleading statements. Specifically, defendants created the false impression that:

  • bluebird could obtain Federal Drug Administration (“FDA”) approval for lovo-cel, gene therapy for sickle cell patients, without any black box warnings for haematological malignancies;
  • bluebird would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen bluebird’s financial position for the lovo-cel launch;
  • as a result, bluebird had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and
  • therefore, bluebird’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: bluebird bio Inc.
股票代号: BLUE
集体诉讼期: April 24, 2023 through December 8, 2023
法院: United States District Court for the District of Massachusetts


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。